Pharmaceutics (Nov 2022)

Photodynamic Opening of the Blood–Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors

  • Oxana Semyachkina-Glushkovskaya,
  • Andrey Terskov,
  • Alexander Khorovodov,
  • Valeria Telnova,
  • Inna Blokhina,
  • Elena Saranceva,
  • Jürgen Kurths

DOI
https://doi.org/10.3390/pharmaceutics14122612
Journal volume & issue
Vol. 14, no. 12
p. 2612

Abstract

Read online

Photodynamic therapy (PDT) is a promising add-on therapy to the current standard of care for patients with glioblastoma (GBM). The traditional explanation of the anti-cancer PDT effects involves the PDT-induced generation of a singlet oxygen in the GBM cells, which causes tumor cell death and microvasculature collapse. Recently, new vascular mechanisms of PDT associated with opening of the blood–brain barrier (OBBB) and the activation of functions of the meningeal lymphatic vessels have been discovered. In this review, we highlight the emerging trends and future promises of immunotherapy for brain tumors and discuss PDT-OBBB as a new niche and an important informative platform for the development of innovative pharmacological strategies for the modulation of brain tumor immunity and the improvement of immunotherapy for GBM.

Keywords